Clinical Trials Logo

Clinical Trial Summary

To date, antiviral treatment is not recommended for chronic hepatitis B patients with a normal ALT level and low viremia. The strategy is to closely monitor the patients. However, evidence suggests that these group are at risk of gradual disease progression and development of hepatocellular carcinoma. Peginterferon eliminates the hepatitis B virus through immune regulation and induction of antiviral protein expression. For patients with low viral load, the clinical cure rate is potentially promising. In this study, we aim to investigate the efficacy and safety of peginterferon alpha-2b therapy in selected chronic hepatitis B patients with normal ALT level and low viremia. It is expected to obtain a satisfactory curative effect. Peginterferon is a marketed drug available in Chinese clinics with indications of anti-hepatitis B virus.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05203055
Study type Interventional
Source Fuzhou General Hospital
Contact Dongliang Li, Professor
Phone 008613665052006
Status Recruiting
Phase Phase 1/Phase 2
Start date December 10, 2021
Completion date December 10, 2023